<PAGE>
================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

       [X]  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
                              EXCHANGE ACT OF 1934

                               For the quarterly period ended September 30, 2001

       [ ]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

                                 For the transition period from ______ to ______


                             LARK TECHNOLOGIES, INC.
        (Exact name of small business issuer as specified in its charter)


         DELAWARE                                          73-1461841
(State or other jurisdiction of                          (IRS Employer
Incorporation or organization)                         Identification No.)

                 9441 WEST SAM HOUSTON PARKWAY SOUTH, SUITE 103
                                HOUSTON, TX 77099
                    (Address of principal executive offices)

                                 (713) 779-3663
                           (Issuer's telephone number)


Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.  Yes [X]   No [ ]

                APPLICABLE ONLY TO ISSUER INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant filed all documents and reports required to be
filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of
securities under a plan confirmed by a court.  Yes [ ]   No [ ]


                      APPLICABLE ONLY TO CORPORATE ISSUERS

As of September 30, 2001, there were 3,516,895 shares of Common Stock, par value
$0.001 per share, outstanding.

Transitional Small Business Disclosure Format (Check one):  Yes [ ]   No [X]

================================================================================
<PAGE>
                             LARK TECHNOLOGIES, INC.

                              INDEX TO FORM 10-QSB
                    FOR THE QUARTER ENDED SEPTEMBER 30, 2001.


Part I   Financial Information (unaudited)
<TABLE>
<CAPTION>
                                                                              Page
                                                                              ----
<S>                                                                            <C>
       Item 1.    Financial Statements

                      Balance Sheet........................................    1

                      Statements of Operations.............................    2

                      Statements of Cash Flows.............................    3

                      Notes to Financial Statements........................    4

       Item 2.    Management's Discussion and Analysis of
                  Financial Condition and Results of Operations............    6

Part II  Other Information.................................................    9

       Item 1.    Legal Proceedings........................................    9

       Item 2.    Changes in Securities....................................    9

       Item 3.    Defaults Upon Senior Securities..........................    9

       Item 4.    Submission of Matters to a Vote of Security Holders......    9

       Item 5.    Other Information........................................    9

       Item 6.    Exhibits and Reports on Form 8-K.........................    9

Signatures.................................................................   11
</TABLE>


                                       i
<PAGE>
                         PART I - FINANCIAL INFORMATION
                          ITEM 1. FINANCIAL STATEMENTS

                             LARK TECHNOLOGIES, INC.
                                  BALANCE SHEET
<TABLE>
<CAPTION>
                                                                               September 30, 2001
                                                                             -----------------------
                                                                                  (Unaudited)
<S>                                                                          <C>
ASSETS
Current assets:
               Cash and cash equivalents                                               $519,100
               Accounts receivable, net                                                $675,370
               Due from related parties                                                 $29,471
               Work-in-process                                                         $127,705
               Prepaid expenses                                                        $137,517
                                                                                ----------------
Total current assets                                                                  1,489,163

Property and equipment, net                                                           1,244,689
Other assets, net                                                                        13,641
                                                                                ----------------
Total assets                                                                         $2,747,493
                                                                                ================

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
               Accounts payable                                                        $444,671
               Notes payable                                                            403,098
               Capital lease obligations-current portion                                190,564
               Accrued expenses                                                         183,598
               Customer deposits                                                        349,488
                                                                                ----------------
Total current liabilities                                                             1,571,419

Note payable-long term portion                                                           43,444
Capital lease obligations-long term portion                                             318,311
Deferred rent expense                                                                    18,540
                                                                                ----------------
Total liabilities:                                                                    1,951,714

Stockholders' equity
               Preferred stock, $0.001 par value:
                    Authorized shares - 2,000,000
                    None issued and outstanding
               Common stock, $0.001 par value:
                    Authorized shares - 8,000,000
                    Issued shares:3,521,395 and
                    outstanding shares: 3,516,895                                         3,521
               Additional paid-in capital                                             2,670,343
               Treasury stock at cost                                                    (4,945)
               Accumulated comprehensive loss                                            (2,811)
               Accumulated deficit                                                   (1,870,329)
                                                                                ----------------
Total stockholders' equity                                                              795,779
                                                                                ----------------
Total liabilities and stockholders' equity                                           $2,747,493
                                                                                ================
</TABLE>

See accompanying notes to the financial statements.


                                       1
<PAGE>
                         PART I - FINANCIAL INFORMATION
                          ITEM 1. FINANCIAL STATEMENTS

                             LARK TECHNOLOGIES, INC.
                            STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
                                                  Three months Ended September 30,                Nine months Ended September 30,
                                              -----------------------------------------       --------------------------------------
                                                    2000                   2001                     2000                   2001
                                              -----------------------------------------       --------------------------------------
                                                            (Unaudited)                                       (Unaudited)
<S>                                             <C>                    <C>                      <C>                    <C>
Revenue:
        Laboratory services                     $1,619,265             $1,279,563               $4,305,192             $4,359,355

Costs and expenses:
        Costs of services                          920,433                792,652                2,623,120              3,104,135
        Sales, general and administrative          534,778                514,884                1,461,503              1,586,954
        Research and development                         0                      0                        0                      0
                                              -------------         --------------           --------------         --------------
Total costs and expenses                         1,455,211              1,307,536                4,084,623              4,691,089
                                              -------------         --------------           --------------         --------------
Operating income (loss)                            164,054                (27,973)                 220,569               (331,734)

Other income and (expense):
        Interest expense                           (18,064)               (22,660)                 (55,087)               (51,430)
        Interest income                              4,212                  3,288                    9,539                 17,685
        Other income                                     0                      0                        0                125,323
                                              -------------         --------------           --------------         --------------
Total other income (expense)                       (13,852)               (19,372)                 (45,548)                91,577
                                              -------------         --------------           --------------         --------------
Income (loss) before income taxes                  150,202                (47,345)                 175,021               (240,157)

Provision for income taxes                           7,876                      0                    7,876                      0
                                              -------------         --------------           --------------         --------------
Net income (loss)                                 $142,326               ($47,345)                $167,145              ($240,157)
                                              =============         ==============           ==============         ==============
Basic and diluted earnings (loss)
        per common share                              0.04                 ($0.01)                   $0.05                 ($0.07)
                                              =============         ==============           ==============         ==============
</TABLE>

See accompanying notes to the financial statements.


                                       2
<PAGE>
                         PART I - FINANCIAL INFORMATION
                          ITEM 1. FINANCIAL STATEMENTS

                             LARK TECHNOLOGIES, INC.
                            STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
                                                                            Nine months ended
                                                                              September 30,
                                                                   ------------------------------------
                                                                         2000                 2001
                                                                   ---------------       --------------
                                                                                (Unaudited)
<S>                                                                      <C>                 <C>
OPERATING ACTIVITIES
Net income (loss)                                                        $167,145            ($240,157)
Adjustments to reconcile net income (loss)
   to net cash provided by (used in) operating activities
               Depreciation and amortization                              263,778              324,171
               Provision for bad debts                                     17,000               13,647
               Changes in operating assets and liabilities:
                    Accounts receivable                                   (45,744)             137,186
                    Inventory                                              37,397              138,562
                    Prepaid expenses                                       51,214               28,629
                    Other Assets                                              360
                    Due from related parties                                1,064              (20,245)
                    Accounts payable                                     (275,249)             (88,223)
                    Accrued expenses                                      (57,259)              66,582
                    Deposits                                              534,698             (649,194)
                                                                   ---------------       --------------
Net cash provided by (used in) operating activities                       694,405             (289,042)

INVESTING ACTIVITIES
Purchases of property and equipment                                      (167,654)             (83,315)
                                                                   ---------------       --------------
Net cash used in investing activities                                    (167,654)             (83,315)

FINANCING ACTIVITIES
Proceeds from issuance of notes payable                                   106,500               92,000
Principal payments on notes payable                                      (250,013)            (106,054)
Principal payments on capital leases                                     (157,784)             (88,543)
Proceeds from exercised stock options                                     172,962                  730
Proceeds from exercised warrants                                           12,500
Redemption of warrants                                                    (31,250)
                                                                   ---------------       --------------
Net cash used in financing activities                                    (147,085)            (101,867)
                                                                   ---------------       --------------
Net increase (decrease) in cash and cash equivalents                      379,665             (474,224)
Cash and cash equivalents at beginning of period                          270,830              993,324
                                                                   ---------------       --------------
Cash and cash equivalents at end of period                               $650,496             $519,100
                                                                   ===============       ==============
</TABLE>

See accompanying notes to the financial statements.


                                        3
<PAGE>
                             LARK TECHNOLOGIES, INC.
                          NOTES TO FINANCIAL STATEMENTS
                                   (UNAUDITED)


1.       ORGANIZATION

         Lark Technologies, Inc., a Delaware corporation (the "Company"), was
formed on November 16, 1994, as a wholly-owned subsidiary of SuperCorp Inc.
("SuperCorp"), for the purpose of merging with Lark Sequencing Technologies,
Inc., a Delaware corporation ("Sequencing"), as outlined in a merger agreement
("Merger Agreement") entered into by SuperCorp and Sequencing on October 28,
1994. SuperCorp approved the Merger Agreement on September 5, 1995 and by the
stockholders of Sequencing on September 12, 1995. As a consequence of the
merger, all of the shares of common and preferred stock of Sequencing were
exchanged for 1,800,000 shares of Common Stock of the Company with a par value
of $0.001 per share and the 200,000 shares of Common Stock of the Company held
by SuperCorp were distributed to the shareholders of SuperCorp. The Company has
succeeded to all of the business previously undertaken by Sequencing. Lark
provides specialized laboratory services for DNA sequencing to biotechnology
researchers.

2.       ACCOUNTING POLICIES

Basis of Presentation

         The accompanying unaudited interim financial statements have been
prepared pursuant to the rules and regulations of the Securities and Exchange
Commission. Certain information in footnote disclosures normally included in
financial statements prepared in accordance with generally accepted accounting
principles have been condensed or omitted pursuant to these rules and
regulations. The accompanying unaudited interim financial statements reflect all
adjustments which the Company considers necessary for a fair presentation of the
results of operations for the interim periods covered and for the financial
condition of the Company at the date of the interim balance sheet. All such
adjustments are of a recurring nature. Results for the interim periods are not
necessarily indicative of results for the year.

         For financial reporting purposes, the merger of the Company and
Sequencing has been accounted for as a recapitalization of Sequencing, and the
historical financial statements of Sequencing prior to the merger became the
financial statements of the Company.

Recently Issued Accounting Standards

In June 1998, the Financial Accounting Standards Board issued Statements of
Financial Accounting Standards No.133, Accounting for Derivative Financial
Instruments and Hedging Activities ("SFAS No.133"). SFAS No.133 requires that
all derivatives be recognized as assets and liabilities and measured at fair
value. The accounting for changes in the fair value of a derivative depends on
the intended use of the derivative and the resulting designation. SFAS No.133,
as amended, is effective for the fiscal years beginning after June 15, 2000 and
early adoption is permitted. Because of the Company's minimal use of
derivatives, management does not anticipate that the adoption of SFAS No.133
will have a significant effect on net income or the financial position of the
Company.

3.       INVENTORY

         Work in process inventory includes the direct and indirect costs
associated with projects that had been started but not yet completed at
September 30, 2001. Direct costs include such items as the cost of labor,
reagents and supplies directly associated with each project. Indirect costs
include such items as general supplies, laboratory management, depreciation, and
costs to operate the lab. These costs are applied to each project on the basis
of direct labor hours incurred for the project, up to the point of measurement,
such as the end of an accounting period. At September 30, 2001, work in process
inventory was $127,705.


                                       4
<PAGE>
4.       NOTES PAYABLE

         On December 7, 2000, the Company renewed its revolving line of credit
and extended the maturity to December 31, 2001. Under the terms of its revolving
line, the Company may borrow up to $600,000 at the bank's prime rate (6.5% at
September 30, 2001) plus 2%. The borrowing base of this line of credit is equal
to 80% of certain accounts receivable that are no more than 90 days old. On
September 30, 2001 the Company had $323,955 outstanding under this line. Under
the terms of the revolving line of credit agreement, the Company is required to
maintain certain financial ratios and a specific level of net worth. As of
September 30, 2001, the Company was not in compliance with one of the required
financial ratios and has obtained a statement from the bank waiving the missed
requirements until December 31, 2001. Management expects the Company will return
to compliance with the required financial ratios prior to December 31, 2001.

         On March 13, 1998, the Company arranged an advised discretionary credit
line for the financing of equipment with the same bank used for the line of
credit described above. Under the terms of this discretionary credit, the
Company was able to borrow up to $600,000 secured by the equipment purchased
with the proceeds of the borrowings. This discretionary credit line provided for
the borrowings of up to 75% of the purchase price of equipment at the bank's
prime plus 1.5%. This credit line provided for repayment terms up to 36 months
and matured on May 31, 1999. On January 5, 1999, the Company borrowed $22,000
against this line of credit for the purchase of lab equipment. As of September
30, 2001, a balance of $2,444 remained on this loan.

         During January 2001, the company arranged an advance term loan facility
to finance the purchase of various pieces of lab equipment with the same bank
that provided the revolving line of credit. On February 26, 2001 the company
borrowed $92,000 under this facility. On that same day, the advance line feature
of this loan converted to a fixed facility requiring monthly payments over a 36
month period at the bank's prime rate plus 2%. As of September 30, 2001, a
balance of $74,111 remained on this loan.

         On March 29, 2001, the Company entered into a capital lease for the
purchase of two additional automated DNA sequencers that cost approximately
$263,000. Under the terms of the 36 months lease, the Company may purchase this
equipment for the residual value at the end of the lease.

         On April 3, 2001, the Company entered into a capital lease for the
purchase of a Multiprobe robotic liquid handling system that cost approximately
$76,000. Under the terms of the 60 months lease, the Company may purchase this
system for a dollar at the end of the lease.

         On June 20, 2001, the Company's U.K. office entered into a capital
lease for the purchase of an automated DNA sequencer that cost approximately
$146,000. Under the terms of the 36 months lease, the Company will become the
owner of the goods at the end of the lease.

5.       EARNINGS PER SHARE

                  The following table sets forth the weighted average shares
outstanding for the computation of basic and diluted earnings per share:

<TABLE>
<CAPTION>
                                               For the three months ending   For the nine months ending
                                                        September 30,              September 30,
                                               ---------------------------   --------------------------
                                                    2000          2001          2000          2001
                                                  ---------     ---------     ---------     ---------
<S>                                               <C>           <C>           <C>           <C>
Weighted average common shares outstanding:       3,499,731     3,516,895     3,455,741     3,516,752
Dilutive securities - employee stock options:       169,729        63,420       223,724       105,831
                                                  ---------     ---------     ---------     ---------
Weighted average common shares outstanding
 Assuming full dilution:                          3,669,460     3,580,315     3,679,465     3,622,583
                                                  =========     =========     =========     =========
</TABLE>

         Options to purchase 454,440 shares of common stock were outstanding
during 2001 but were not included in the computation of diluted earnings per
share because the effect would be antidilutive.


                                       5
<PAGE>
6.       COMMITMENTS AND CONTINGENCIES

Stock Options and Warrants

         During the quarter, 235,000 options were issued to various directors of
the Company.

Patent License Agreement

         Effective June 15, 1995, the Company entered into an exclusive patent
sub-license agreement with another biotech company. The agreement grants to the
Company an exclusive license to certain "Licensed Patent Rights" of this third
party and requires the Company to perform research and development efforts as
defined in the agreement. The Company is required to pay the third party a
royalty of 25% to 50% of all consideration the Company receives as a result of
sales of licensed products and licensed processes or a sub-license or assignment
of the Company's rights under the agreement. If the Company does not meet the
research and development milestones as defined in the agreement, or is unable to
successfully commercialize the results of the research and development efforts,
the agreement will terminate. Otherwise, the agreement will terminate upon the
dissolution of the Company or the expiration of the "Licensed Patent Rights".
The Company may also terminate the agreement with 60 days written notice to the
third party.

         The Company wrote off $16,749 in the second quarter assets related to
"Licensed Patent Rights" as Management felt that the likelihood that these
patents would be issued was unlikely.

Sponsored Research Contract

         On October 6, 1998, the Company announced the restructuring of its
senescence technology development program. Sennes Drug Innovations, Inc., the
Company's licensor for the senescence technology, which originated with a third
party, recently appointed a new president. This appointment was allowed by the
settlement of various technology transfer issues between the third party and
Sennes. This new president will represent the Sennes technologies, including the
senescence gene technology licensed to the Company, to third parties. The
Company's license for senescence technologies remains intact.

         The senescence technology includes genes involved in regulating the
four senescence gene pathways. Senescence is the normal physiological process
that controls cellular immortality. Immortal cells are closely related to cancer
and can add insights into aging and abnormal development.

Commitments and Contingencies

         The Company is involved in various legal proceedings that have arisen
in the ordinary course of business. In the opinion of management, based on
consultations with counsel and a review of the facts, the ultimate liability to
the Company will not have a material effect on the financial position of the
Company.

         ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
                 RESULTS OF OPERATIONS

         The following discussion and analysis should be read in conjunction
with the Financial Statements and the accompanying Notes herein, and is
qualified entirely by the foregoing and by other more detailed financial
information appearing elsewhere.

GENERAL

         Lark is a leading molecular biology Contract Research Organization
(CRO) providing services to the pharmaceutical and biotechnology industries
worldwide. Lark's service portfolio consists of various DNA sequencing and
molecular biology services as follows:


                                       6
<PAGE>
     o    Automated DNA Sequencing Services. Lark applies automated sequencing
          techniques to generate high throughput DNA sequence and fast
          turnaround screening information, including genome sequencing, shotgun
          sequencing and shotgun library construction services.

     o    Genetic Stability Testing Services. Lark's genetic stability testing
          services are used to characterize Master Cell Banks, Manufacturers'
          Working Cell Banks and PostProduction Cell Samples from bacterial,
          yeast and cell cultures. Genetic stability testing is used to analyze
          a production strain's stability and demonstrate that the expression
          system has not undergone any mutations or rearrangements that would
          affect the integrity of the product. This service assists companies
          producing genetically manufactured products to optimize production
          yields, determine product purity, and support regulatory submissions.
          This service was introduced in late 1996.

     o    Quantitative Polymerase Chain Reaction (PCR) Services. Lark uses
          Quantitative PCR techniques to measure the distribution and expression
          of target DNA or RNA in a customer's sample from cultured cells,
          microorganisms, or tissues such as brain, lung, liver, and kidneys.

     o    Array Services. Lark uses automated PCR techniques to produce
          molecular materials used in the construction of biochip arrays.

     o    Molecular Biology Services. Lark offers a variety of molecular biology
          services including library screening, library prescreening, southern
          blot analysis, subcloning, plasmid preparation and PCR amplification.
          Lark consults with its customers to customize a broad range of
          molecular biology projects.

          In 1995 Lark undertook a senescence gene discovery program for its own
account. Although several genes were discovered in this program, lack of gene
functionality coupled with license issues caused Lark to reduce its funding for
this program. Lark continues to work towards license issue resolution and
eventual potential sublicense agreements.

RESULTS OF OPERATIONS

         GROSS REVENUES. Gross revenues decreased 21% from $1,619,265 to
$1,279,563 for the three-month periods ended September 30, 2000 and 2001,
respectively. Gross revenue increased 1% from $4,305,192 to $4,359,355 for the
nine-month periods ended September 30, 2000 and 2001 respectively. The decrease
in revenues for the quarter was due to delays in the receipt of several
projects, which we expect to complete in the fourth quarter.

         COSTS OF SERVICES. Costs of services consist primarily of labor and
laboratory supplies. Costs of services decreased 14% from $920,433 to $792,652
for the three-month periods ended September 30, 2000 and 2001, respectively.
Costs of services increased 18% from $2,623,120 to $3,104,135 for the nine-month
periods ended September 30, 2000 and 2001, respectively. The decrease for the
quarter was mainly due to the decreased revenue. Approximately one-half of the
increase for the nine months was due to the finished goods inventory of QPCR
assays being written down to zero as management deemed the assays to be
unsaleable. The remaining increase in costs of services for the nine months was
due to the additional variable costs required to produce the additional revenue
for the period, restructuring costs associated with operations, as well as,
development costs required to enhance the Company's lab operation. These extra
costs were incurred to significantly increase operating efficiency of lab
operations. See variability of future operating results below for further
details. Costs of services as a percentage of revenue were 57% and 62% for the
three-month periods ending September 30, 2000 and 2001respectively and 61% and
71% for the nine-month periods ended September 30, 2000 and 2001, respectively

                  SALES, GENERAL AND ADMINISTRATIVE EXPENSES. Sales, general and
administrative expenses consist primarily of salaries and related costs,
depreciation, amortization, legal and professional costs, rent, travel, and
advertising. Sales, general and administrative expenses decreased 4% from
$534,778 to $514,883 for the three-month periods ended September 30, 2000 and
2001, respectively. The decrease resulted mainly from a reduction in head count.
Sales, general and administrative expenses increased 9% from $1,461,503 to
$1,586,954 for the nine-month period ended September 30, 2000 and 2001,
respectively. This increase is mainly the result of increased legal expenses
that were incurred earlier in the year. Sales, general and administrative
expenses as a percentage of


                                       7
<PAGE>
revenue were 33% and 40% for the three-month and 34% and 36% for the nine-month
periods ended September 30, 2000 and 2001, respectively.

         VARIABILITY OF FUTURE OPERATING RESULTS In 1998, the Company adopted a
new business model that broadened its services and expanded its customer base.
The favorable results reported for the third quarter of 1999 reflected the first
profitable quarter for this business model. That success continued into the
fourth quarter of 1999 and was interrupted, in the first quarter of 2000, only
by the extra expenses and disruption incurred to relocate the Company to its new
headquarters and lab facility in Houston during January of 2000. The profitable
trend continued into the third quarter of 2000 although earnings were somewhat
lower due to the recruiting expenses. In the first quarter of 2001, the Company
began a reengineering process to significantly enhance productivity in its lab
operations. These enhancements were a combination of process changes made
possible by the addition of new automated equipment. This equipment, which cost
approximately $263,000, is designed to increase operating efficiency and
profitability. The changes made to production methods in the first quarter were
significant and required a considerable amount of development time and cost to
accomplish. These development costs were the principal reason for the higher
than normal cost of services in the first quarter of 2001. Additional equipment
was acquired in third quarter to continue upgrading the current instrumentation,
automation and throughput. This was done through the assumption of a lease for
two automated DNA sequencers. These development costs combined with the
additional selling expenses were the main contributors to the loss sustained in
the quarter ended September 30, 2001. Management believes these changes will
enable the Company to significantly increase revenue and profitability in the
future. As the Company continues to grow, it expects to further automate its
processes in order to be even more competitive and to further increase its
market share. The Company continues to seek large contracts and diversify its
customer base.


         LIQUIDITY AND CAPITAL RESOURCES. Operating cash flow was $694,405 and
($289,042) for the nine-month periods ended September 30, 2000 and 2001,
respectively. The negative operating cash flow for the period ending September
30, 2001 occurred primarily as a result of applying almost $650,000 of customer
deposits to sales.

         On December 7, 2000, the Company renewed its revolving loan facility
through December 31, 2001, and may now borrow up to $600,000 under the terms of
the new credit line.

         During January 2001, the company arranged an advance term loan facility
to finance the purchase of various pieces of lab equipment with the same bank
that provided the revolving line of credit. On February 26, the company borrowed
$92,000 under this facility. On that same day, the advance line feature of this
loan converted to a fixed facility requiring monthly payments over a 36 month
period at the bank's prime rate plus 2%.

         As of September 30, 2001, the Company was not in compliance with some
of the required financial ratios and has obtained a statement from the bank
waiving the missed requirements until December 31, 2001. Management believes the
Company will be in compliance with the required financial ratios on or before
December 31, 2001.

         On March 29, 2001, the Company entered into a capital lease for the
purchase of two additional automated DNA sequencers. Under the terms of the 36
months lease, the Company may purchase this equipment for a nominal amount at
the end of the lease.

         On April 3, 2001, the Company entered into a capital lease for the
purchase of a Multiprobe robotic liquid handling system. Under the terms of the
60 months lease, the Company may purchase this system for a nominal amount at
the end of the lease.

         On June 20, 2001, the Company's U.K. office entered into a capital
lease for the purchase of an automated DNA sequencer. Under the terms of the 36
months lease, the Company will become the owner of the goods at the end of the
lease. See note 4 to financial statements for further details of the Company's
borrowing facilities.

         MATERIAL COMMITMENTS. The Company currently has no outstanding material
commitments.


                                       8
<PAGE>
                          PART II - OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

         On June 29, 2000 Joel S. Kanter sued the Company in U.S. District Court
for the Southern District of Texas, Houston Division. The Company entered into a
letter of intent with the "Kanter Group" in 1999 providing for Mr. Kanter to
conduct, or invest in, a proposed $1,320,000 private offering of Company stock.
The transaction was not completed by the time specified in the letter of intent
(on or before November 1, 1999) and Mr. Kanter and the Company continued to work
on the offering for a time thereafter. Mr. Kanter alleges the Company did not
allow him to complete the offering and seeks damages for the breach of the
letter of intent and for reliance damages for his expenses following expiration
of the letter of intent. The Company's position is that there was no binding
agreement, that the letter of intent, by its own terms, prevents Kanter from
recovering and that Kanter imposed material conditions to the completion of the
transaction which were not set forth in the letter of intent. The litigation is
in its initial stages of discovery and the Company intends to file a motion for
summary judgment shortly. The Company intends to vigorously defend the lawsuit
and Management believes that it is without merit.

ITEM 2.  CHANGES IN SECURITIES
         Not applicable.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES
         Not applicable.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
         Not applicable

ITEM 5.  OTHER INFORMATION
         Not applicable.

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

         No reports on Form 8-K were filed during the quarter ending
September 30, 2001.

     Index of Exhibits
     -----------------

         2.1(1)   The Agreement of Merger of November 18, 1994, between Lark
                  Technologies, Inc. and Lark Sequencing Technologies, Inc.
                  providing for the merger of Lark Sequencing Technologies, Inc.
                  into the Company.

         3.1(1)   Bylaws of Lark Technologies, Inc., as amended.

         3.2(1)   The Certificate of Incorporation of Lark Technologies, Inc.,
                  as amended.

         4.1(3)   Lark Technologies, Inc. 2000 Stock Option Plan adopted by the
                  Company.

       10.13(2)   Agreement entered into by and between the Company and Genomyx
                  Corporation.

       10.14(2)   The portion of the Minutes of the Executive Session of the
                  Meeting of the Board of Directors of the Company held December
                  8, 1995, establishing and defining the bonus plan for 1996
                  under which the chief executive officer, chief financial
                  officer, and other employees may receive cash bonuses as part
                  of their compensation.


                                       9
<PAGE>

(1)  Incorporated by reference from the Company's Registration Statement on Form
     S-4 dated August 14, 1995, Commission File No. 33-90424. The exhibit
     numbering system used in Form S-4 differed from that used in this Form
     10-QSB (8a, 2d, 2c, 6b, 6c, 6d-1, and 6f, respectively).

(2)  Incorporated by reference from the Company's Form 10-QSB for the quarterly
     period ended March 31, 1996.

(3)  Incorporated by reference from the Company's Registration Statement on Form
     S-8 dated September 21, 2000, Commission File No. 333-46280.



                                       10
<PAGE>
                                   SIGNATURES


In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.



                                      Lark Technologies, Inc.
                                               (Registrant)



Date November 8, 2001                      /s/ CARL BALEZENTIS
                                      -------------------------------------
                                               Carl Balezentis
                                      President and Chief Executive Officer




                                       11